      |
|
||||||||
|
Dr. Frank van Leeuwen
The mission our laboratory is to investigate the cell biology and genetics of childhood malignancies. Currently our efforts are aimed at the identification and characterization of (novel) signaling pathways that contribute to therapy resistance in pediatric Acute Lymphoblastic Leukemia (ALL). Other research interests include regulation of (tumor) cell adhesion and migration by the actomyosin cytoskeleton and the role of nonconventional myosins in immune regulation. |
||||||||
|
Recent key publications Clark, K., M. Langeslag, C.G. Figdor, and F.N. van Leeuwen. 2007. Myosin II and mechanotransduction: a balancing act. Trends Cell Biol. 17:178-86. Clark, K., M. Langeslag, B. van Leeuwen, L. Ran, A.G. Ryazanov, C.G. Figdor, W.H. Moolenaar, K. Jalink, and F.N. van Leeuwen. 2006. TRPM7, a novel regulator of actomyosin contractility and cell adhesion. Embo J. 25:290-301. Clark, K., J. Middelbeek, N.A. Morrice, C.G. Figdor, E. Lasonder, and F.N. van Leeuwen. 2008. Massive autophosphorylation of the Ser/Thr-rich domain controls protein kinase activity of TRPM6 and TRPM7. PLoS ONE3:e1876. Kuiper, R.P., E.F. Schoenmakers, S.V. van Reijmersdal, J.Y. Hehir-Kwa, A.G. van Kessel, F.N. van Leeuwen, and P.M. Hoogerbrugge. 2007. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia. 21:1258-66. van Helden, S.F., M.M. Oud, B. Joosten, N. Peterse, C.G. Figdor, and F.N. van Leeuwen. 2008. PGE2-mediated podosome loss in dendritic cells is dependent on actomyosin contraction downstream of the RhoA-Rho-kinase axis. J Cell Sci. 121:1096-106. |
||||||||
